[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE312601T1 - Poröse arzneistoffmatrizen und deren herstellungsverfahren - Google Patents

Poröse arzneistoffmatrizen und deren herstellungsverfahren

Info

Publication number
ATE312601T1
ATE312601T1 AT00939365T AT00939365T ATE312601T1 AT E312601 T1 ATE312601 T1 AT E312601T1 AT 00939365 T AT00939365 T AT 00939365T AT 00939365 T AT00939365 T AT 00939365T AT E312601 T1 ATE312601 T1 AT E312601T1
Authority
AT
Austria
Prior art keywords
drug
porous matrix
forming agent
pore forming
volatile
Prior art date
Application number
AT00939365T
Other languages
English (en)
Inventor
Julie Straub
Howard Bernstein
Donald E Chickering Iii
Sarwat Khatak
Greg Randall
Original Assignee
Acusphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE312601(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/433,486 external-priority patent/US6395300B1/en
Application filed by Acusphere Inc filed Critical Acusphere Inc
Application granted granted Critical
Publication of ATE312601T1 publication Critical patent/ATE312601T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Epoxy Compounds (AREA)
AT00939365T 1999-05-27 2000-05-25 Poröse arzneistoffmatrizen und deren herstellungsverfahren ATE312601T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13632399P 1999-05-27 1999-05-27
US15865999P 1999-10-08 1999-10-08
US09/433,486 US6395300B1 (en) 1999-05-27 1999-11-04 Porous drug matrices and methods of manufacture thereof
US18631000P 2000-03-02 2000-03-02
PCT/US2000/014578 WO2000072827A2 (en) 1999-05-27 2000-05-25 Porous drug matrices and methods of manufacture thereof

Publications (1)

Publication Number Publication Date
ATE312601T1 true ATE312601T1 (de) 2005-12-15

Family

ID=27495210

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00939365T ATE312601T1 (de) 1999-05-27 2000-05-25 Poröse arzneistoffmatrizen und deren herstellungsverfahren

Country Status (18)

Country Link
EP (1) EP1180020B2 (de)
JP (1) JP4722295B2 (de)
KR (2) KR100752000B1 (de)
CN (1) CN1240373C (de)
AT (1) ATE312601T1 (de)
AU (1) AU768022B2 (de)
BR (1) BR0010984A (de)
CA (1) CA2371836C (de)
DE (1) DE60024811T3 (de)
DK (1) DK1180020T4 (de)
ES (1) ES2250141T5 (de)
HK (2) HK1048956B (de)
IL (2) IL146659A0 (de)
MX (1) MXPA01012106A (de)
NO (1) NO323761B1 (de)
NZ (1) NZ516083A (de)
TW (1) TWI274589B (de)
WO (1) WO2000072827A2 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
ATE397581T1 (de) 1999-04-06 2008-06-15 Sepracor Inc O-desmethylvenlafaxin-succinat
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US6589557B2 (en) * 2000-06-15 2003-07-08 Acusphere, Inc. Porous celecoxib matrices and methods of manufacture thereof
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE10059020A1 (de) * 2000-11-28 2002-05-29 Gruenenthal Gmbh Parenteral applizierbare Darreichungsformen
WO2002054868A2 (en) 2000-12-21 2002-07-18 Inhale Therapeutic Syst Pulmonary delivery of polyene antifungal agents
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
NZ539046A (en) * 2001-01-18 2006-11-30 Pharmacia & Upjohn Co Llc Chemotherapeutic self-emulsifying microemulsion compositions of paclitaxel with improved oral bioavailability
CA2666611A1 (en) † 2001-02-12 2002-08-22 Wyeth Novel succinate salt of o-desmethyl-venlafaxine
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
WO2002094231A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
US7105178B2 (en) 2001-07-17 2006-09-12 Sun Pharmaceutical Industries Limited Cardiotonic composition
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
JP4384503B2 (ja) * 2002-03-20 2009-12-16 アルカーメス，インコーポレイテッド レボドパの肺送達
JP4452970B2 (ja) 2002-03-27 2010-04-21 日本臓器製薬株式会社 ジクロフェナクナトリウム経口製剤
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
EP1556018A1 (de) * 2002-09-30 2005-07-27 Acusphere, Inc. Poröse mikropartikeln zur inhalation mit verlängerter freigabe
WO2004089375A1 (en) 2003-03-31 2004-10-21 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
ATE520935T1 (de) 2003-05-21 2011-09-15 Alexza Pharmaceuticals Inc Verwendung einer schicht aus festem brennstoff, verfahren zum erstellen einer solchen schicht und zugehörige heizvorrichtung
GB0401947D0 (en) 2004-01-28 2004-03-03 Unilever Plc Porous bodies and method of production thereof
KR100681660B1 (ko) * 2004-03-17 2007-02-09 주식회사종근당 방출제어 펠릿의 약제학적 조성물
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
EP1681056A1 (de) 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Verfahren zur Herstellung von Lansoprazol
US20080200533A1 (en) * 2005-07-04 2008-08-21 Ramu Krishnan Drug or Pharmaceutical Compounds and a Preparation Thereof
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
GB0523638D0 (en) 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
WO2007086039A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin A method of producing porous microparticles
KR100917809B1 (ko) * 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
EP2139533A2 (de) * 2007-04-27 2010-01-06 Endo Pharmaceuticals Solutions Inc. Freisetzungsmittel für implantate und anwendungsverfahren dafür
PT103743B (pt) * 2007-05-16 2013-01-15 Hovione Farmaciencia S A Processo para preparar derivados de 21-disódio fosfato de pregnanos.
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
MX2010002179A (es) 2007-08-24 2010-04-27 Stichting Het Nl Kanker I Composicion para el tratamiento de enfermedades neoplasicas.
CA2701695A1 (en) * 2007-10-09 2009-04-16 Novartis Ag Pharmaceutical formulation of valsartan
KR101024742B1 (ko) * 2007-12-31 2011-03-24 주식회사 삼양사 탁산 함유 양친성 블록 공중합체 미셀 조성물 및 그 제조방법
US9801818B2 (en) 2007-12-31 2017-10-31 Samyang Biopharmaceuticals Corporation Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
EP2318350A4 (de) * 2008-07-25 2012-11-28 Alphapharm Pty Ltd ATOVAQUON MIT PARTIKELGRÖSSENDURCHMESSERBEREICH (D90) VON ÜBER 3 muM BIS ZU ETWA 10 muM
EP2328555A2 (de) * 2008-08-22 2011-06-08 Slotervaart Participaties BV Zusammensetzungen zur behandlung von neoplastischen erkrankungen
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
EP2411137B1 (de) 2009-03-27 2016-09-07 Bend Research, Inc. Sprühtrocknungsverfahren
EP2611529B1 (de) 2010-09-03 2019-01-23 Bend Research, Inc. Sprühtrocknungsverfahren
WO2012031133A2 (en) 2010-09-03 2012-03-08 Bench Research, Inc. Spray-drying apparatus and methods of using the same
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
WO2012114342A1 (en) 2011-02-23 2012-08-30 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
CN103301095B (zh) * 2012-03-13 2016-04-13 中国科学院上海药物研究所 一种用于提高普罗布考口服吸收的多孔复合载药组合物及其制备方法
US20150150788A1 (en) * 2012-06-22 2015-06-04 The University Of Queensland Method and composition for delivering a compound through a biological barrier
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US11464741B2 (en) 2014-06-11 2022-10-11 SpecGx LLC Spray dried compositions having different dissolution profiles and processes for their preparation
JP6650933B2 (ja) 2014-10-31 2020-02-19 ベンド リサーチ， インコーポレイテッド マトリックス中に分散された活性薬剤ドメインを形成するためのプロセス
WO2016100949A2 (en) * 2014-12-18 2016-06-23 Windgap Medical, Inc. Method and compositions for dissolving or solubilizing therapeutic agents
CN114010628A (zh) * 2015-06-04 2022-02-08 克里蒂泰克公司 紫杉烷颗粒及其用途
EP3324930A2 (de) 2015-09-16 2018-05-30 DFB Soria, LLC Freisetzung von wirkstoffnanopartikeln und verfahren zur verwendung davon
DK3439635T3 (da) * 2016-04-04 2021-03-08 Crititech Inc Formuleringer til behandling af fast tumor
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR101965708B1 (ko) * 2016-08-30 2019-04-04 이화여자대학교 산학협력단 스폰지 유사 구조를 갖는 고분자 미립자 및 이의 제조방법
EP3595633B1 (de) 2017-03-15 2023-07-05 DFB Soria, LLC Topische therapie zur behandlung von hautmalignitäten mit taxan nanopartikeln
BR112019023948A2 (pt) 2017-06-09 2020-06-09 Crititech Inc tratamento de cistos epiteliais por injeção intracística de partículas antineoplásicas
JP6840869B2 (ja) 2017-06-14 2021-03-10 クリチテック，インコーポレイテッド 肺障害の治療方法
JP2020536052A (ja) 2017-10-03 2020-12-10 クリティテック・インコーポレイテッド 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達
US11278492B2 (en) 2018-01-05 2022-03-22 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
EP3765035A4 (de) 2018-03-16 2021-10-27 DFB Soria, LLC Topische therapie zur behandlung von zervikalen intraepithelialen neoplasien (cin) und gebärmutterhalskrebs unter verwendung von taxannanopartikeln
MX2021009038A (es) * 2019-01-29 2021-08-16 Bayer Healthcare Llc Composiciones topicas de naproxeno en gel.
CA3138885A1 (en) * 2019-05-10 2020-11-19 Anomera Inc. Porous cellulose microparticles and methods of manufacture thereof
MX2023006678A (es) 2020-12-08 2023-08-22 Ruminant Biotech Corp Ltd Mejoras en los dispositivos y métodos para suministrar sustancias a los animales.
CN113081971A (zh) * 2021-05-14 2021-07-09 江西中医药大学 一种中药多孔核壳型复合粒子粉体及其制备方法和应用
CN117538462B (zh) * 2024-01-10 2024-03-26 地奥集团成都药业股份有限公司 一种氨氯地平贝那普利胶囊有关物质的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1265615A (de) * 1970-09-10 1972-03-01
NL7313626A (nl) † 1973-10-04 1975-04-08 Philips Nv Gecombineerde inrichting voor het produceren en sselen van warmte met een warmte ver- ende inrichting.
GB8322007D0 (en) † 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
IL82245A (en) * 1986-04-25 1990-07-26 Basf Ag Preparation of spray-dried granules of active ingredients
EP0655237A1 (de) * 1993-11-27 1995-05-31 Hoechst Aktiengesellschaft Medizinische Aerosolformulierung
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
DE69732306T2 (de) † 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
IL135126A0 (en) * 1997-09-29 2001-05-20 Inhale Therapeutic Syst Perforated microparticles and methods of use and preparation thereof
JP4758525B2 (ja) * 1998-03-20 2011-08-31 武田薬品工業株式会社 生理活性ポリペプチドの徐放性製剤およびその製造法
US6423345B2 (en) † 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery

Also Published As

Publication number Publication date
AU768022B2 (en) 2003-11-27
HK1048956B (zh) 2006-07-28
NZ516083A (en) 2003-08-29
CA2371836A1 (en) 2000-12-07
CA2371836C (en) 2006-01-31
KR100883477B1 (ko) 2009-02-16
CN1240373C (zh) 2006-02-08
EP1180020B1 (de) 2005-12-14
JP4722295B2 (ja) 2011-07-13
DE60024811T2 (de) 2006-09-14
MXPA01012106A (es) 2003-06-30
BR0010984A (pt) 2002-04-30
ES2250141T5 (es) 2009-11-05
KR20070069219A (ko) 2007-07-02
JP2003500438A (ja) 2003-01-07
CN1365274A (zh) 2002-08-21
HK1094775A1 (en) 2007-04-13
AU5445900A (en) 2000-12-18
KR100752000B1 (ko) 2007-08-28
TWI274589B (en) 2007-03-01
DE60024811D1 (de) 2006-01-19
WO2000072827A9 (en) 2002-01-31
NO323761B1 (no) 2007-07-02
EP1180020A2 (de) 2002-02-20
NO20015753L (no) 2002-01-28
WO2000072827A3 (en) 2001-01-25
EP1180020B2 (de) 2009-06-24
IL146659A0 (en) 2002-07-25
HK1048956A1 (en) 2003-04-25
WO2000072827A2 (en) 2000-12-07
IL146659A (en) 2010-05-31
DK1180020T3 (da) 2006-03-27
DE60024811T3 (de) 2010-01-07
DK1180020T4 (da) 2009-10-05
ES2250141T3 (es) 2006-04-16
NO20015753D0 (no) 2001-11-26
KR20020011992A (ko) 2002-02-09

Similar Documents

Publication Publication Date Title
ATE312601T1 (de) Poröse arzneistoffmatrizen und deren herstellungsverfahren
RU2420290C2 (ru) Твердые, пригодные для орального употребления фармацевтические формы применения, содержащие ривароксабан с модифицированным высвобождением
JP4334869B2 (ja) 溶解性または経口吸収性の改善された組成物
KR880004806A (ko) 분무 건조 아세트아미노펜
WO2001095877A3 (en) Porous celecoxib matrices and methods of manufacture thereof
RU2003111950A (ru) Препарат, содержащий натеглинид
TW450811B (en) Lyophilizate of lipid complex of water insoluble camptothecins
KR960000247A (ko) 사이클로스포린a 함유 조성물 및 그의 제조방법
Sun et al. A novel enteric positioning osmotic pump capsule-based controlled release system of sinomenine hydrochloride: In vitro and in vivo evaluation
KR100583065B1 (ko) 프로그램화 및 펄스화 방출식 다립형 의약 제형 및 그의 제조 방법
JPS58116414A (ja) ニカルジピン持続性製剤用球形顆粒およびその製造法
JP6666352B2 (ja) デュタステリド含有固体分散体及びこれを含む組成物
AU2003235156B2 (en) Solid dispersion composition
Xia et al. Approaches to developing fast release pellets via wet extrusion-spheronization
ES2549309T3 (es) Formulación terapéutica nueva
TH78112B (th) เนื้อสารยารูพรุน และวิธีการของการผลิตของสิ่งเหล่านั้น
Minocha et al. SOlubility enhancement of poorly water soluble drugs by various techniques
TH78112A (th) เนื้อสารยารูพรุน และวิธีการของการผลิตของสิ่งเหล่านั้น
CN100475203C (zh) 制备雷公藤内酯醇分子微囊的方法
Saritha et al. Preparation and evaluation of solid dispersions of Ofloxacin
CN103251557A (zh) 一种非洛地平纳米混悬剂及其制备方法
JP2616946B2 (ja) 肝類洞小孔拡張・増加剤
CN107213132A (zh) 一种灯盏花素渗透泵控释片及其制备方法
KR100981750B1 (ko) 분무-건조 과립 및 그의 제조방법
EP0323762A1 (de) Hustenstillende Zusammensetzungen und ein Verfahren zu deren Herstellung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1180020

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1180020

Country of ref document: EP